Trial Profile

A first-in-human study of ANN-002 in treatment of hereditary angioedema

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 26 Nov 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Nov 2018 According to an Adverum Biotechnologies media release, the company will not submit an IND application, as it plans to conduct additional preclinical studies to determine the best gene therapy candidate to advance for the rare disease programs.
01 Nov 2018 According to an Adverum Biotechnologies media release, the company will not submit an IND application for ADVM-053 for the treatment of hereditary angioedema (HAE) in the fourth quarter of 2018.
08 Nov 2017 According to an Adverum Biotechnologies media release, the Company also plans to file an IND application with the FDA in the second half of 2018.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com